Related references
Note: Only part of the references are listed.Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study
A. Necchi et al.
ANNALS OF ONCOLOGY (2015)
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer
Y. Yamada et al.
ANNALS OF ONCOLOGY (2015)
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
L. Bazzola et al.
BRITISH JOURNAL OF CANCER (2015)
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
L. Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2015)
Final results of phase II trial of doxorubicin HCI liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma
D. J. Straus et al.
ANNALS OF ONCOLOGY (2014)
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
U. Urner-Bloch et al.
ANNALS OF ONCOLOGY (2014)
A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
Eileen M. O'Reilly et al.
ANNALS OF SURGERY (2014)
A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte-Macrophage Colony Stimulating Factor-Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer
Lei Zheng et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity
Sylvain Ladoire et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy
Jianliang Yang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
The stromal compartments in pancreatic cancer: Are there any therapeutic targets?
Serena Lunardi et al.
CANCER LETTERS (2014)
CCL2/CCR2-Dependent Recruitment of Functional AntigenPresenting Cells into Tumors upon Chemotherapy
Yuting Ma et al.
CANCER RESEARCH (2014)
Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy
Christian P. Pallasch et al.
CELL (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Danger signalling during cancer cell death: origins, plasticity and regulation
A. D. Garg et al.
CELL DEATH AND DIFFERENTIATION (2014)
Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling
A. Ko et al.
CELL DEATH AND DIFFERENTIATION (2014)
Impact of myeloid cells on the efficacy of anticancer chemotherapy
Laura Senovilla et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Targeting FAK in human cancer: from finding to first clinical trials
Vita M. Golubovskaya
FRONTIERS IN BIOSCIENCE-LANDMARK (2014)
Maspin influences response to doxorubicin by changing the tumor microenvironment organization
Tiziana Triulzi et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
High hydrostatic pressure induces immunogenic cell death in human tumor cells
Jitka Fucikova et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Yoshihiko Ichikawa et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial
Yong Sang Hong et al.
LANCET ONCOLOGY (2014)
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy et al.
LANCET ONCOLOGY (2014)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts et al.
LANCET ONCOLOGY (2014)
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
Sung Hoon Noh et al.
LANCET ONCOLOGY (2014)
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Bernardo Tavora et al.
NATURE (2014)
An alternative DNA damage pathway to apoptosis in hematological cancers
John M. Luk et al.
NATURE MEDICINE (2014)
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers
Francesca Cottini et al.
NATURE MEDICINE (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways
Stephen W. Morton et al.
SCIENCE SIGNALING (2014)
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase
Yan Liu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Systems biology of cisplatin resistance: past, present and future
L. Galluzzi et al.
CELL DEATH & DISEASE (2014)
STK4 Inhibition Promotes YAP1-Mediated Apoptosis in Hematologic Cancers
Cancer Discovery (2014)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi et al.
ONCOTARGET (2014)
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Eric R. Lutz et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2014)
Novel insights into the mechanism of action of lenalidomide
Michaela Semeraro et al.
ONCOIMMUNOLOGY (2014)
Why should we need the gut microbiota to respond to cancer therapies?
Sophie Viaud et al.
ONCOIMMUNOLOGY (2014)
Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy
Yuting Ma et al.
ONCOIMMUNOLOGY (2014)
Radioimmunotherapy for oncological indications
Norma Bloy et al.
ONCOIMMUNOLOGY (2014)
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
Abdul Qader Sukkurwala et al.
ONCOIMMUNOLOGY (2014)
Immunostimulatory monoclonal antibodies in cancer therapy
Fernando Aranda et al.
ONCOIMMUNOLOGY (2014)
Two is better than one Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
Shashi A. Gujar et al.
ONCOIMMUNOLOGY (2014)
Trial Watch Adoptive cell transfer for anticancer immunotherapy
Fernando Aranda et al.
ONCOIMMUNOLOGY (2014)
Trial watch: IDO inhibitors in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
Lidia Robert et al.
ONCOIMMUNOLOGY (2014)
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Encouse B. Golden et al.
ONCOIMMUNOLOGY (2014)
Trial Watch Oncolytic viruses for cancer therapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2014)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp et al.
ONCOIMMUNOLOGY (2014)
Trial Watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Trial Watch Tumor-targeting monoclonal antibodies in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
Abhishek D. Garg et al.
AUTOPHAGY (2013)
Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
Abhishek D. Garg et al.
BIOFACTORS (2013)
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
T. Hoehler et al.
BRITISH JOURNAL OF CANCER (2013)
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial
U. O. Njiaju et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Inducers of immunogenic cancer cell death
Aleksandra M. Dudek et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Crosstalk between ER stress and immunogenic cell death
Oliver Kepp et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
Yuting Ma et al.
IMMUNITY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
Patrizia Vici et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Decoding cell death signals in liver inflammation
Catherine Brenner et al.
JOURNAL OF HEPATOLOGY (2013)
Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer
Jun-Yang Lu et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
The role of the immune system in governing host-microbe interactions in the intestine
Eric M. Brown et al.
NATURE IMMUNOLOGY (2013)
Metabolic targets for cancer therapy
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells
Chiara Riganti et al.
PLOS ONE (2013)
Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells
Helene Bugaut et al.
PLOS ONE (2013)
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida et al.
SCIENCE (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
Immunogenic Cell Death: Can It Be Exploited in PhotoDynamic Therapy for Cancer?
Elisa Panzarini et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Trial watch Monoclonal antibodies in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells Killing two birds with one stone
Chiara Riganti et al.
ONCOIMMUNOLOGY (2013)
Is there a future for adoptive cell transfer in melanoma patients?
Michal J. Besser
ONCOIMMUNOLOGY (2013)
Immune correlates of melanoma survival in adoptive cell therapy
Agnes Fermin Lee et al.
ONCOIMMUNOLOGY (2013)
Current trends of anticancer immunochemotherapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells
Mara Cirone et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Lenalidomide-based immunochemotherapy
Michaela Semeraro et al.
ONCOIMMUNOLOGY (2013)
Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors
Nadine M. Lerret et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Adoptive cell transfer for anticancer immunotherapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity
Abhishek D. Garg et al.
ONCOIMMUNOLOGY (2013)
ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy
Yuting Ma et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Anticancer radioimmunotherapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Immunogenic cell death in radiation therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2013)
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
Ben C. Creelan et al.
ONCOIMMUNOLOGY (2013)
Trial watch Cardiac glycosides and cancer therapy
Laurie Menger et al.
ONCOIMMUNOLOGY (2013)
Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model
Pedram Kharaziha et al.
CANCER RESEARCH (2012)
Mitochondrial Control of Cellular Life, Stress, and Death
Lorenzo Galluzzi et al.
CIRCULATION RESEARCH (2012)
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Abhishek D. Garg et al.
EMBO JOURNAL (2012)
Radiation Therapy to Convert the Tumor Into an In Situ Vaccine
Silvia C. Formenti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Bacteria and host interactions in the gut epithelial barrier
Hiroshi Ashida et al.
NATURE CHEMICAL BIOLOGY (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Mitochondria: master regulators of danger signalling
Lorenzo Galluzzi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Primary Effusion Lymphoma Cell Death Induced by Bortezomib and AG 490 Activates Dendritic Cells through CD91
Mara Cirone et al.
PLOS ONE (2012)
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Laura Senovilla et al.
SCIENCE (2012)
Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota
Janelle C. Arthur et al.
SCIENCE (2012)
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Laurie Menger et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
P. Kharaziha et al.
CELL DEATH & DISEASE (2012)
Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Lorenzo Galluzzi et al.
CELL REPORTS (2012)
Activation of dendritic cells by tumor cell death
Mara Cirone et al.
ONCOIMMUNOLOGY (2012)
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
Mickael Michaud et al.
ONCOIMMUNOLOGY (2012)
Anticancer activity of cardiac glycosides At the frontier between cell-autonomous and immunological effects
Oliver Kepp et al.
ONCOIMMUNOLOGY (2012)
The emergence of phox-ER stress induced immunogenic apoptosis
Abhishek D. Garg et al.
ONCOIMMUNOLOGY (2012)
Trial Watch Experimental Toll-like receptor agonists for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Trial watch Prognostic and predictive value of the immune infiltrate in cancer
Laura Senovilla et al.
ONCOIMMUNOLOGY (2012)
Treating metastatic cancer with nanotechnology
Avi Schroeder et al.
NATURE REVIEWS CANCER (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma
Mathieu Boulin et al.
ANTI-CANCER DRUGS (2011)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
Giovanna Schiavoni et al.
CANCER RESEARCH (2011)
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Jitka Fucikova et al.
CANCER RESEARCH (2011)
Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells
Ilenia Pellicciotta et al.
GYNECOLOGIC ONCOLOGY (2011)
Dendritic Cell and Macrophage Heterogeneity In Vivo
Daigo Hashimoto et al.
IMMUNITY (2011)
Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy
Yuting Ma et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Greta Garrido et al.
JOURNAL OF IMMUNOLOGY (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins et al.
ONCOGENE (2011)
DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown
Abhishek D. Garg et al.
PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Abhishek D. Garg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Lorenzo Galluzzi et al.
CANCER RESEARCH (2010)
Decoding Cell Death Signals in Inflammation and Immunity
Laurence Zitvogel et al.
CELL (2010)
About the cutaneous targets of bexarotene in CTCL patients
Anne Chantal Knol et al.
EXPERIMENTAL DERMATOLOGY (2010)
Absence of modulation of CD4+CD25high regulatory T cells in CTCL patients treated with bexarotene
Anne Chantal Knol et al.
EXPERIMENTAL DERMATOLOGY (2010)
Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects
Emmanuel S. Antonarakis et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
Alicia F. C. Okines et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis
Faraaz B. Chekeni et al.
NATURE (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Development of Monocytes, Macrophages, and Dendritic Cells
Frederic Geissmann et al.
SCIENCE (2010)
JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis
V. Tomlinson et al.
CELL DEATH & DISEASE (2010)
Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma
Robert J. Rounbehler et al.
CANCER RESEARCH (2009)
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
Theocharis Panaretakis et al.
EMBO JOURNAL (2009)
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Michael R. Elliott et al.
NATURE (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone
Jens Hoffmann et al.
CANCER RESEARCH (2008)
Ornithine Decarboxylase Inhibition by α-Difluoromethylornithine Activates Opposing Signaling Pathways via Phosphorylation of Both Akt/Protein Kinase B and p27Kip1 in Neuroblastoma
Dana-Lynn T. Koomoa et al.
CANCER RESEARCH (2008)
PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory Feedback Loop
Eleonora Lapi et al.
MOLECULAR CELL (2008)
Revisiting the biological roles of PAI2 (SERPINB2) in cancer
David R. Croucher et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis
M. Obeid et al.
CELL DEATH AND DIFFERENTIATION (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib
Thibault de la Motte Rouge et al.
CANCER RESEARCH (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Mitochondrial membrane permeabilization in cell death
Guido Kroemer et al.
PHYSIOLOGICAL REVIEWS (2007)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mitochondria as therapeutic targets for cancer chemotherapy
L. Galluzzi et al.
ONCOGENE (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Select forms of tumor cell apoptosis induce dendritic cell maturation
S Demaria et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Share Paper
